Healthcare Industry News: human embryonic stem cell
News Release - March 5, 2007
Stem Cell Innovations Names Ian Lyons, Ph.D., U.S. Chief Scientific Officer
HOUSTON--(HSMN NewsFeed)--Stem Cell Innovations, Inc. (OTCBB: SCLL ) today announced Ian Lyons, Ph.D., has been appointed Chief Scientific Officer, U.S. Dr. Lyons joins Helmuth van Es, Ph.D., Chief Scientific Officer, Europe, as co-leader of Stem Cell Innovation's scientific programs. Dr. Lyons helped develop and characterize several of the human embryonic stem cell lines that are on the list approved for federally funded research in the U.S."Stem Cell Innovations is poised to become a leader in the use of human, pluripotent stem cells in drug discovery, toxicology and cell therapy and I am excited by this opportunity to build an entirely new platform in stem cell biology," said Ian Lyons, Ph.D. "I am enthusiastic about combining my cell biology background with the drug discovery expertise of Helmuth van Es to bring a new level of cell-based modeling to the pharmaceutical and biotechnology industries."
Dr. Lyons was previously Research Area Manager (Stem Cells), and Principal Scientist for Invitrogen, Inc. where his responsibilities included developing the company's portfolio of products for human stem cell research Prior to joining Invitrogen, Dr. Lyons was employed in a variety of senior positions at BresaGen, Ltd., one of the first companies to concentrate on stem cell biology. He is the author of numerous scientific publications dealing with both human and animal cell biology as well as molecular biology.
Dr.. Lyons received his Ph.D. from the University of Melbourne in Australia. After receiving his doctorate, Dr. Lyons began his work in stem cell research during a postdoctoral fellowship at the Walter and Eliza Hall Institute of Medical Research, Victoria, Australia.
About Stem Cell Innovations, Inc.
Stem Cell Innovation (SCI) is a cell biology company with offices in Scotch Plains, NJ, and facilities in Houston, TX, and Leiden, the Netherlands. SCI's proprietary, human pluripotent stem cells, known as PluriCells, have the potential to aid in drug discovery, toxicology, and cell therapy. The company is in the process of making its patented pluripotent cell lines, which are eligible for federal funding in the U.S., widely available to universities and other not-for-profit institutions to rapidly advance stem cell research.
Stem Cell Innovations is positioned to become a leading provider of toxicology testing and discovery systems for the pharmaceutical, chemical, and nutraceutical industries around the world. The development of the proprietary PluriCell technology greatly expands the Company's currently marketed ACTIVTox® human liver cell-based toxicology offerings.
Additional information is available at www.stemcellinnovations.com.
ACTIVTox and PluriCells are trademarks of Stem Cell Innovations, Inc.
Forward Looking Statement
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward looking statements. Forward-Looking statements are not statements of historical facts, but rather reflect our current expectations concerning future events and results. We use words such as "expects", "intends", "believes", "may", "will" and "anticipates" to indicate forward-looking statements. Because theses forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including, but not limited to, those risks and uncertainties detailed in the Company's periodic reports filed with the Securities and Exchange Commission. We caution that these risk factors may not be exhaustive. We operate in a continually changing business environment, and new risk factors emerge from time to time. We cannot predict these new risk factors, nor can we assess the effect, if any, of the new risk factors on our business or the extent to which any factor or combination of factors may cause actual results to differ from those expressed or implied by these forward-looking statements.
If any one or more or these expectations and assumptions proves incorrect, actual results will likely differ materially from those contemplated by the forward-looking statements. Even if all of the foregoing assumptions and expectations prove correct, actual results may still differ materially from those expressed in the forward-looking statements as a result of factors we may not anticipate or that may be beyond our control. While we cannot assess the future impact that any of these differences could have on our business, financial condition, results of operations and cash flows or the market price of shares of our common stock, the difference could be significant. We do not undertake to update any forward-looking statements made by us, whether as a result of new information, future events or otherwise. You are cautioned.
Source: Stem Cell Innovations
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
